Drug Database
BE

bevacizumab (Stivant / BE 1040V / BE1040V)

✓ Approved

AryoGen Pharmed · VEGFA · 单克隆抗体

什么是 bevacizumab?

bevacizumab 是一种单克隆抗体,由AryoGen Pharmed研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Stivant, BE 1040V, BE1040V
公司AryoGen Pharmed
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedCancer medicine2026-11-17

Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK-Mutated Non-Small-Cell Lung Cancer.

Kang Eun Joo EJ, Park Sehhoon S, Kim Tae Min TM, Han Ji-Youn JY et al.

The phase 3 ATTLAS study demonstrated that atezolizumab plus bevacizumab, carboplatin, and paclitaxel (ABCP) improved progression-free survival compared with pemetrexed-carboplatin/cisplatin (PC) in EGFR/ALK-mutated non-small-cell lung cancer after tyrosine kinase inhibitor failure. We report patient-reported quality of life (QoL) outcomes. Patients received ABCP (atezolizumab 1200 mg, bevacizumab 15 mg/kg, carboplatin AUC 5-5.5, paclitaxel 175 mg/m2) or PC (pemetrexed 500 mg/m2, carboplatin AUC 5.0, or cisplatin 70 mg/m2) every 3 weeks. QoL was assessed using EORTC QLQ-C30 and QLQ-LC13. Primary endpoints were changes in global health status/QoL (GHS/QoL) from baseline at weeks 9 and 24, and median time to deterioration (TTD; ≥ 10-point decline). Of 228 randomized patients (2:1), 146 (ABCP) and 68 (PC) completed ≥ 1 QoL assessment. Baseline GHS/QoL was comparable between arms. Early GHS and physical functioning scores were numerically lower with ABCP but stabilized by week 24, with no significant differences at week 9 (-4.66; p = 0.247) or week 24 (-7.39; p = 0.305). Toxicity-related symptoms (neuropathy, alopecia, and pain) were more frequent with ABCP, whereas cancer-related symptom improvements (cough, dyspnea, and hemoptysis) occurred in both arms without significant differences. Median TTD was 3.48 months (ABCP) versus 6.90 months (PC; p = 0.160). Despite impairment in symptoms commonly associated with chemotherapy, no significant between-group difference in overall QoL was detected between ABCP and PC. Stable GHS/QoL and improvement in cancer-related symptoms were observed alongside appropriate toxicity management. The protocol was approved by the institutional review board of Samsung Medical Center (IRB no. 2019-03-027) and participating centers (ClinicalTrials.gov identifier: NCT03991403).

PMID 43040603
阅读全文 →
PubMedBMC cancer2026-11-16

Cross-database thromboembolic reporting signals for ovarian cancer therapies: a focus on bevacizumab.

Fu Yao Y, Ao Hui H, Qian Zhengyue Z, Sheng Chunyan C et al.

Thromboembolic events (TEs) can disrupt ovarian cancer treatment and adversely affect outcomes. Post-marketing reporting patterns across systemic therapies and regulatory databases remain poorly characterized. We analyzed the FDA Adverse Event Reporting System (FAERS; 2004Q1-2025Q1), Canada Vigilance (2002-2025), and Japanese Adverse Drug Event Report database (JADER; 2004-2025). Reports involved ovarian, fallopian tube, or primary peritoneal cancer and prespecified systemic therapies. MedDRA preferred term-validated definitions identified venous thromboembolism (VTE), arterial thromboembolism (ATE), and their union (any_TE). We assessed ROR, PRR, chi-square, information component, and IC025 within each database; cross-database replication was the primary criterion. Pooled and covariate-adjusted analyses were supportive. Bevacizumab subgroup, co-medication, time-to-onset (TTO), fatal-outcome, network, and drug-target Mendelian randomization (MR) analyses provided descriptive or exploratory context. After excluding male-coded records, 55,271 reports met inclusion, including 1,296 TE cases. Seven of 39 drug-event combinations replicated in at least two databases. Bevacizumab alone replicated for any_TE, VTE, and ATE in all three systems. In FAERS, RORs were 2.28 (95% CI 1.96-2.65; IC025 0.81) for any_TE and 2.38 (1.94-2.93; IC025 0.81) for VTE. The ATE ROR was 2.34 (1.91-2.87; IC025 0.79). Paclitaxel replicated for any_TE and ATE, whereas doxorubicin replicated for any_TE and VTE. Rucaparib appeared in one database and was not assessable for replication. Only 1,757/45,025 (3.9%) FAERS reports had usable dates. Median recorded TTO was 90 days for bevacizumab and 13 days for carboplatin and paclitaxel; these selected intervals were interpreted descriptively. Genetically proxied VEGFA inhibition was associated with stroke (OR 1.17, 95% CI 1.09-1.26; P = 1.33e-05), but not with VTE or pulmonary embolism. Bevacizumab showed the most reproducible reporting signals across all three databases for composite, venous, and arterial thromboembolism. Together with greater MR concordance for arterial outcomes, this phenotype-resolved pattern motivates separate biological hypotheses for VTE and ATE. Clinically, it reinforces vigilance for both phenotypes during bevacizumab-containing ovarian cancer treatment and supports phenotype-specific prospective validation.

PMID 43035654
阅读全文 →
PubMedGastroenterologia y hepatologia2026-11-16

Bevacizumab as Rescue Therapy for Refractory Gastrointestinal Angiodysplasia and Gastric Antral Vascular Ectasia.

Garcia-Sagué B B, Frisancho L E LE, Romero-Velastegui S S, García-Iglesias P P et al.

PMID 43039310
阅读全文 →
PubMedJournal of cancer research and clinical oncology2026-11-16

Profiling the tumor microenvironment of a hepatocellular carcinoma patient with primary resistance to immunotherapy plus anti-angiogenic therapy but exceptional response to chemotherapy plus bevacizumab.

Xu Qin Q, Zhu Rui R, Wang Zirui Z, Zhao Chengjian C et al.

Hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM) carries a poor prognosis, and treatment options after failure of anti-angiogenic targeted agents combined with immune checkpoint inhibitor (ICI) remain limited. An adult patient with advanced HCC exhibited primary resistance to three sequential immunotherapy-based regimens: first-line lenvatinib plus camrelizumab (progressive lung metastases), second-line atezolizumab plus bevacizumab (rapid tumor marker surge), and third-line atezolizumab plus regorafenib (new liver and adrenal metastases within 3 months, suspicious for rapid disease progression following immunotherapy). Fortunately, fourth-line mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and fluorouracil) plus bevacizumab induced a partial response (PR) with significant tumor shrinkage and substantial declines in AFP and PIVKA-II. The case had shown a total progression-free survival (PFS) for more than 21 months until the latest follow-up in June 2026. Then, we performed 24-plex spatial tissue profiling of the primary tumor. The tumor microenvironment revealed three core features: immune-desert (lymphocytes < 5%, no tertiary lymphoid structures, exhausted PD-1 + CD8+ T cells), hyper-vascularization with disorganized endothelium and severe pericyte deficiency (αSMA coverage 2.9%), and high perivascular tumor proliferation. This unique "immune-desert, vessel-rich, rapidly proliferating" signature potentially accounts for the striking oxaliplatin-based chemotherapy sensitivity despite primary ICI-anti-angiogenic therapy resistance. This case suggests that in selected HCC patients with multiline ICI-anti-angiogenic therapy resistance, prompt transition to chemotherapy plus bevacizumab may yield profound responses.

PMID 43037761
阅读全文 →
PubMedClinical Medicine Insights. Oncology2026-11-16

Clinical and Molecular Predictors of Early Tumor Shrinkage and Depth of Response in Metastatic Colorectal Cancer Treated with mFOLFOXIRI plus Bevacizumab: A Retrospective Study from Vietnam.

Pham Anh Tuan AT, Mai Ngan Thi Kim NTK, Huy Trinh Le TL, Nguyen Hau Xuan HX et al.

Early tumor shrinkage (ETS) and depth of response (DpR) are increasingly recognized as early efficacy endpoints and potential surrogate markers of long-term outcomes in metastatic colorectal cancer (mCRC). However, determinants of ETS and DpR in patients receiving intensive first-line chemotherapy remain insufficiently characterized, particularly in Asian populations. We retrospectively analyzed patients with histologically confirmed mCRC treated with first-line mFOLFOXIRI plus bevacizumab at Hanoi Medical University Hospital between January 2020 and June 2025. ETS was defined as a ≥20% reduction in target lesion diameters at the first radiological assessment (8 weeks), and DpR as the maximum percentage reduction from baseline. Logistic and linear regression were used to identify factors associated with ETS and DpR. PFS was analyzed according to ETS and DpR. Seventy-two patients were included. ETS was observed in 56.9%, with a median DpR of 40% and median time to maximal response of 4.9 months. Primary tumor resection showed a trend toward higher ETS rates in multivariable analysis, whereas no patient with a BRAF V600E mutation achieved ETS, although the number of BRAF-mutant tumors was limited. ETS was significantly associated with greater DpR. In multivariable analysis, ETS, completion of 12 treatment cycles, and ≥50% CEA reduction at week 8 were associated with greater DpR. RAS, BRAF, and PIK3CA mutations were not independently associated with DpR. Median PFS was 14.5 months, with significantly longer PFS in patients achieving ETS or higher DpR. In patients with metastatic colorectal cancer treated with first-line mFOLFOXIRI plus bevacizumab, ETS and early CEA reduction were associated with greater tumor shrinkage. Both ETS and DpR were also associated with longer progression-free survival, supporting their potential role as early markers of treatment response.

PMID 43036419
阅读全文 →
PubMedJournal of neuro-oncology2026-11-16

Stereotactic radiosurgery outcomes in high-grade meningiomas harboring NF2 alterations.

Sahin Mustafa C MC, Hori Yusuke S YS, Lam Fred C FC, Kalra Neeraj N et al.

To evaluate lesion-level local control and treatment-attributable toxicity after CyberKnife radiosurgery for high-grade meningiomas harboring NF2 alterations. Adults with grade 2 or 3 meningiomas treated with CyberKnife between 2015 and 2025 were retrospectively reviewed. Inclusion required tumor sequencing demonstrating a pathogenic or likely pathogenic NF2 alteration and evaluable post-treatment imaging. Integrated central nervous system World Health Organization grade incorporated the 2021 WHO molecular criteria. Time to local progression was estimated using Kaplan-Meier analysis; exploratory Cox regression accounted for patient-level clustering. Eleven patients with 19 treated targets were included. All had prior surgery, and 7 (63.6%) had prior radiation. NF2 pathogenic/likely pathogenic alterations occurred in 11 patients; none had confirmed clinical or germline NF2. Median lesion-level imaging follow-up was 48.6 months. Local progression occurred in 9 targets (47.4%). Median time to local progression was 35.4 months; local control at 1, 2, and 3 years was 88.2%, 62.7%, and 47.8%, respectively. Lesion volume > 3 cc was associated with shorter time to local progression (hazard ratio, 4.26; p = 0.025). Common Terminology Criteria for Adverse Events grade 3 radiation necrosis or post-radiation edema requiring corticosteroids and bevacizumab occurred in one lesion (5.3%); no CyberKnife-related mortality occurred. High-grade meningiomas harboring NF2 alterations showed frequent local progression after CyberKnife, particularly among larger lesions. Severe treatment-attributable toxicity occurred in one of 19 treated-targets. Lesion volume may inform radiosurgical risk assessment, but multicenter validation is needed.

PMID 43035551
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab